Insider Purchases: Inside the Buy
Tag: Growth Stocks
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.
📈 Hamilton Lane (HLNE): The Toll Booth on a Trillion-Dollar Private Markets Highway
Hamilton Lane (HLNE) may be one of the most attractive alternative asset managers on the market today. Massive insider buying, a growing dividend, a trillion-dollar asset footprint, and expanding private-wealth opportunities combine to create a compelling long-term investment story.
⚡ Celsius Holdings (CELH): Wall Street Panicked. Insiders Bought the Dip
Celsius Holdings (CELH) may no longer be just a trendy fitness energy drink brand. With explosive 138% revenue growth, synchronized insider buying, Alani Nu integration success, and PepsiCo’s distribution engine accelerating expansion, the stock increasingly looks like a high-growth GARP opportunity hiding beneath a brutal valuation reset.
☕ Black Rock Coffee Bar (BRCB): The Hypergrowth Coffee Chain Wall Street May Have Oversold
Black Rock Coffee Bar (NASDAQ: BRCB) may be one of the market’s more fascinating small-cap growth stories hiding beneath a brutal selloff. With insider buying accelerating, revenue climbing nearly 24%, and profitability improving, investors are beginning to wonder whether Wall Street overshot the downside.
🎲 Flutter Entertainment (FLUT): Betting on the House at a 12x Discount
Flutter Entertainment (FLUT) has collapsed 69% from its highs, yet insiders are aggressively buying shares while FanDuel continues dominating U.S. sports betting. Is Wall Street underpricing one of the world’s most powerful gambling platforms?
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.
🏗️ HubSpot (HUBS): From “Hubris” to “Hand-over-Fist”?
HubSpot (HUBS) just delivered strong Q1 2026 results, but the stock still plunged as investors questioned AI monetization, sales cycles, and valuation. With the CEO, founder-CTO, and director buying shares, institutions owning the float, revenue growing 23%, and valuation metrics finally looking reasonable, HUBS may be shifting from “growth at any price” to a serious GARP contender. 🏗️🤖📈
⚖️ LegalZoom (LZ): The “Lawsuit-Proof” Balance Sheet?
LegalZoom (LZ) is becoming one of the most fascinating battleground stocks of 2026. With the CEO buying shares for the first time, institutions owning more than 100% of float, elevated short interest, and a debt-free balance sheet generating real free cash flow, bulls believe the legal-tech platform could be dramatically undervalued. Bears counter that AI could commoditize core services. At roughly 70% below all-time highs, the courtroom battle is officially underway. ⚖️🚀
🚀 Upstart Stock: Founder Buys $5M as AI Lending Underdog Faces Short-Squeeze Setup
Upstart stock is back in Wall Street’s drama zone: insider buying, massive short interest, AI lending growth, cash-flow concerns, and a possible bank-charter catalyst. High risk? Absolutely. Boring? Not even close.